Drug prices are up for negotiation on 15 Medicare Part D prescription drugs, including popular weight loss drugs such as Ozempic.

The Centers for Medicare & Medicaid Services says the 15 drugs are Ozempic, Rybelsus and Wegovy; Trelegy Ellipta; Xtandi; Pomalyst; Ibrance; Ofev; Linzess; Calquence; Austedo and Austedo XR; Breo ...

Popular weight loss drugs like Ozempic and Wegovy have been added ... “For some people this is a big deal,” U.S. Health and ...

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might ...

Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...

Changes may be on the horizon regarding the cost of diabetes and weight loss drug titans like Ozempic and Wegovy. The Biden administration has announced the next round of prescription drugs selected ...

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

In August of 2024, the U.S. Department of Health and Human Services began negotiating drug prices for 10 different types of medication covered by Medicare Part D. The groundwork for the negotiations ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The Centers for Medicare & Medicaid Services wants to lower the cost for 15 more drugs including Ozempic and Wegovy.